Abbott’s new AI-powered coronary imaging platform, Ultreon 1.0 Software, has received CE mark approval. It can now be sold and marketed throughout Europe.
The platform, which combines optical coherence tomography (OCT) data with advanced AI algorithms, was designed to assist clinicians during percutaneous coronary intervention and other stenting procedures by evaluating calcium blockages and measuring the diameter of a patient’s blood vessels.
“Increased adoption of OCT imaging, when combined with advanced technology like AI, allows cardiologists to have a more precise and measurable way of supporting patients undergoing coronary stent procedures,” Nick West, MD, chief medical officer and divisional vice president of global medical affairs for Abbott’s vascular business, said in a prepared statement. “Ultreon Software can potentially improve physician and patient experience by utilizing a systematic process, reducing variability and increasing accuracy of diagnosis and application of therapies.”
Abbott is still working toward regulatory approvals in the United States and Japan.
Michael has more than 16 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.